Electrophysiologic and antiarrhythmic effects of the new class III antiarrhythmic drug KCB-328 in experimental canine atrial flutter

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 6, Issue 3, 2001, Pages 297-306

  Rahme, Marc M ^a   Ungab, Gilanthony ^a   Wadhwa, Manish ^a   Al Kandari, Fawziah ^a   Yao, Biguang ^a   Gupta, Anuj ^a   Lee, Kiho ^b   Kim, Hak Yeop ^b   Feld, Gregory K ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b C and C Research Laboratories   (South Korea)

Author keywords

Atrial flutter; Atrial refractoriness; Class III antiarrhythmic; Electrophysiology; KCB 328

Indexed keywords

ANTIARRHYTHMIC AGENT; N [3 AMINO 4 [2 [N (3,4 DIMETHOXYPHENETHYL) N METHYLAMINO]ETHOXY]PHENYL]METHANESULFONAMIDE; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRUSH TRAUMA; DOG; DOSE RESPONSE; DRUG EFFECT; HEART ATRIUM CONDUCTION; HEART ATRIUM FLUTTER; HEART ATRIUM PACING; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; HEART RIGHT ATRIUM; HEART VENTRICLE ARRHYTHMIA; HEMODYNAMICS; NONHUMAN; PR INTERVAL; PRIORITY JOURNAL; QT INTERVAL; RR INTERVAL;

EID: 0035731744     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840100600310     Document Type: Article

References (35)

1. Induction and maintenance of atrial fibrillation - Importance of the duration and dispersion of atrial refractoriness and electrical remodeling
2. Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs
3. Effect of atrial fibrillation on atrial refractoriness in humans
4. Atrial fibrillation begets atrial fibrillation
5. Increased dispersion of "refractoriness" in patients with idiopathic atrial fibrillation
6. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs
7. Electrophysiological and antiarrhythinic effects of the atrial selective 5-HT4 receptor antagonist RS- 100302 in 1003K experimental atrial flutter and fibrillation
8. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide in an experimental canine model of pacing-induced atrial fibrillation
9. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter
10. Pharmacologic conversion and suppression of experimental atrial flutter: Differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction
11. Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental atrial flutter: Significance of changes in refractoriness and conduction
12. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: Role of prolongation of refractory period and depression of conduction to excitable gap
13. Mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation
14. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation
15. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation
16. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter
17. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation
18. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: A multi-center, double-blind crossover study of flecainide and placebo with transtelephonic monitoring
19. Low-dose Amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter
20. Amiodarone in the management of refractory atrial fibrillation
21. Amiodarone to prevent recurrence of atrial fibrillation
22. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide
23. Mechanism of flecainide's rate-dependent actions on action potential duration in canine atrial tissue
24. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm
25. Atrial fibrillation: Is there a safe and highly effective pharmacological treatment?
26. Synthesis and biological activity of KCB-328 and its analogues: Novel class III antiarrhythmic agents with little reverse frequency dependence
27. KCB-328: A novel class III antiarrhythmic agent with little reverse frequency dependence in isolated guinea pig myocardium
28. Antiarrhythmic effects of a novel class III drug, KCB- 328, on canine ventricular arrhythmia models
29. Activation patterns in experimental canine atrial flutter produced by right atnial crush injury
30. Mechanisms of double potentials recorded during sustained atrial flutter in the canine right atrial crush-injury model
31. Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: A comparison with UK-68798, E-40301, and dl-sotalol
32. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class Ill antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia
33. Effects of dofetilide on membrane currents in sinoatrial node cells of rabbit
34. Computer aided development of antiarrhythmic agents with class IIIa properties
35. Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes